Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Xultophy use in adults with type 2 diabetes in Japan (NN9068-4743)
jRCT1051210008Completed
- Sponsor
- Novo Nordisk
- Start
- Apr 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label, single-arm trial of insulin degludec + liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoint: Change in HbA1c from baseline to 26 weeks. Started Apr 2021; status: completed.
02
Drugs
insulin degludec + liraglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT1051210008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1051210008.